--- title: "Maridebart Cafraglutide (MariTide) | PepTracker Pro" url: https://peptrackerpro.com/peptides/maridebart-cafraglutide description: "Amgen's once-monthly injectable GIP receptor antagonist and GLP-1 receptor agonist, showing up to 20% weight loss in phase 2 trials with a unique mechanism that blocks GIP while activating GLP-1." lang: en --- Skip to main content **Educational information only.** This site does not provide medical advice. Read full disclaimer (https://peptrackerpro.com/disclaimer) **Research-only content.** This page is for educational purposes and does not constitute medical advice. Read full disclaimer → (https://peptrackerpro.com/research-disclaimer) # Maridebart Cafraglutide (MariTide) Medium Evidence Amgen's once-monthly injectable GIP receptor antagonist and GLP-1 receptor agonist, showing up to 20% weight loss in phase 2 trials with a unique mechanism that blocks GIP while activating GLP-1. Aliases MariTide +2 more Evidence Medium Evidence Last Updated 2026-06-20 Reading Time 3 min ## What It Is Maridebart cafraglutide (MariTide) is a bispecific antibody-peptide conjugate developed by Amgen that combines GIP receptor antagonism with GLP-1 receptor agonism in a single once-monthly injectable molecule. Unlike dual agonists such as tirzepatide that activate both GIP and GLP-1 receptors, MariTide takes the opposite approach to GIP — blocking it rather than stimulating it. This unique mechanism challenges the prevailing hypothesis that GIP agonism contributes to weight loss and suggests that GIP antagonism may provide complementary metabolic benefits. Phase 2 results published in the New England Journal of Medicine demonstrated mean weight reductions of up to 20% in participants with obesity at 52 weeks, with no weight-loss plateau observed, indicating potential for continued weight reduction beyond one year. In participants with type 2 diabetes and obesity, weight loss reached up to 17% with HbA1c reductions of up to 2.2 percentage points. Full Phase 2 results were presented at the American Diabetes Association 85th Scientific Sessions in 2025, confirming dose-dependent weight loss across all cohorts. The once-monthly dosing schedule represents a significant convenience advantage over weekly injectables in the GLP-1 class. Amgen launched the MARITIME Phase 3 program in 2025, comprising six global studies evaluating MariTide across obesity/overweight (MARITIME-1), type 2 diabetes with obesity (MARITIME-2), cardiovascular outcomes, heart failure, kidney disease, and obstructive sleep apnea. As of May 2026, enrollment is advancing across the MARITIME program, with Phase 3 results expected in 2027–2028. MariTide is not yet FDA-approved for any indication and remains an investigational new drug. Also known as: MariTide, AMG 133, Maridebart cafraglutide ## Regulatory Status Investigational — Phase 3 Currently in the MARITIME phase 3 clinical program. MARITIME-1 evaluates obesity/overweight; MARITIME-2 evaluates type 2 diabetes with obesity. Additional phase 3 studies target cardiovascular, heart failure, kidney disease, and OSA outcomes. No FDA approval yet. Effective: 2025 View FDA Source (https://www.maritimestudy.com/) ## Why Researchers Study It MariTide's GIP antagonist/GLP-1 agonist mechanism is mechanistically distinct from every other incretin-based obesity therapy. Its once-monthly dosing and absence of a weight-loss plateau at 52 weeks make it a compelling candidate for long-term obesity management. Researchers are particularly interested in whether GIP antagonism provides metabolic advantages over GIP agonism, and whether the antibody-peptide conjugate format can extend pharmacodynamic activity beyond what traditional peptide modifications achieve. ## Proposed Mechanisms - Antagonizes GIP receptors, potentially reducing GIP-mediated lipogenesis and adipose tissue expansion - Activates GLP-1 receptors to promote satiety, slow gastric emptying, and enhance insulin secretion - Antibody-peptide conjugate format extends half-life to enable once-monthly dosing - Dual mechanism may reduce compensatory hunger rebound observed with GLP-1-only agents - Continued weight loss without plateau at 52 weeks suggests sustained metabolic adaptation ## Evidence Snapshot Medium Evidence Low Medium High | Study Type | Model | Outcome | Link | | --- | --- | --- | --- | | Phase 2 RCT | Adults with obesity, no T2D (52 weeks) | Up to 20% mean weight loss with no plateau; dose-dependent response across multiple dose levels | Source: https://www.nejm.org/doi/full/10.1056/NEJMoa2504214 | | Phase 2 RCT | Adults with obesity and T2D (52 weeks) | Up to 17% mean weight loss; HbA1c reduction up to 2.2 percentage points | Source: https://www.nejm.org/doi/full/10.1056/NEJMc2514331 | | Phase 3 (ongoing) | MARITIME-1: obesity/overweight, 72 weeks | Enrollment ongoing; primary endpoint is percent change in body weight | Source: https://clinicaltrials.gov/study/NCT06858878 | ## Commonly Discussed Benefits Weight Management: https://peptrackerpro.com/benefits/weight-management Metabolism: https://peptrackerpro.com/benefits/metabolism Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Fat Loss: https://peptrackerpro.com/benefits/fat-loss Researching Maridebart Cafraglutide (MariTide)? Track it, set reminders, and keep notes in the free app. Track in App (https://app.peptrackerpro.com/?add=maridebart-cafraglutide) ## Safety & Cautions - Not yet FDA-approved — all data is from clinical trials - Phase 2 gastrointestinal side effects (nausea, vomiting, diarrhea) were consistent with GLP-1 class effects - Long-term safety beyond 52 weeks not yet established - GIP antagonism is a novel mechanism with limited long-term human data - Phase 3 MARITIME results expected 2027–2028 ## Comparisons See how Maridebart Cafraglutide (MariTide) compares to related peptides: Maridebart Cafraglutide (MariTide) vs Cagrilintide: https://peptrackerpro.com/compare/maridebart-cafraglutide-vs-cagrilintide Maridebart Cafraglutide (MariTide) vs MET-097i: https://peptrackerpro.com/compare/maridebart-cafraglutide-vs-met-097i Maridebart Cafraglutide (MariTide) vs Retatrutide: https://peptrackerpro.com/compare/maridebart-cafraglutide-vs-retatrutide Maridebart Cafraglutide (MariTide) vs Semaglutide: https://peptrackerpro.com/compare/maridebart-cafraglutide-vs-semaglutide Maridebart Cafraglutide (MariTide) vs Survodutide: https://peptrackerpro.com/compare/maridebart-cafraglutide-vs-survodutide Maridebart Cafraglutide (MariTide) vs Tirzepatide: https://peptrackerpro.com/compare/maridebart-cafraglutide-vs-tirzepatide Maridebart Cafraglutide (MariTide) vs HRS9531 (KAI-9531): https://peptrackerpro.com/compare/maridebart-cafraglutide-vs-hrs9531 ## Calculator Tools Use our research tools to explore dosing and reconstitution data: Reconstitution Calculator: https://peptrackerpro.com/calculators ## Citations 1. [1] Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial. NEJM 2026 PubMed (https://www.nejm.org/doi/full/10.1056/NEJMoa2504214) 2. [2] Once-Monthly Maridebart Cafraglutide in Obesity — A Phase 2 Trial (Correspondence). NEJM 2026 PubMed (https://www.nejm.org/doi/full/10.1056/NEJMc2514331) 3. [3] Amgen MARITIME Phase 3 Program Overview PubMed (https://www.amgen.com/stories/2025/06/inside-amgens-phase-3-maritime-program---advancing-the-future-of-obesity-care) 4. [4] ClinicalTrials.gov — MARITIME-1 Study (NCT06858878) PubMed (https://clinicaltrials.gov/study/NCT06858878) ### Keep researching in the app - Log Maridebart Cafraglutide (MariTide) to your private tracker - Set a dosing reminder - Compare it side-by-side with your stack Open PepTracker Pro Free: https://app.peptrackerpro.com/?add=maridebart-cafraglutide Browse more peptides: https://peptrackerpro.com/peptides ## Related Peptides ### Cagrilintide High Evidence A long-acting amylin analog studied for appetite regulation; NDA filed for CagriSema (cagrilintide + semaglutide) combination in December 2025, with FDA review expected in 2026. Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/cagrilintide \+ Compare: https://peptrackerpro.com/compare?select=cagrilintide Track in App: https://app.peptrackerpro.com/?add=cagrilintide ### MET-097i Medium Evidence An ultra-long-acting GLP-1 receptor agonist designed for both once-weekly and once-monthly subcutaneous dosing, delivering double-digit weight loss with class-leading gastrointestinal tolerability in mid-stage trials. Weight Management: https://peptrackerpro.com/benefits/weight-management Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation View Details: https://peptrackerpro.com/peptides/met-097i \+ Compare: https://peptrackerpro.com/compare?select=met-097i Track in App: https://app.peptrackerpro.com/?add=met-097i ### Retatrutide High Evidence An investigational triple agonist (GIP/GLP-1/glucagon) studied for obesity and metabolic disease. Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss View Details: https://peptrackerpro.com/peptides/retatrutide \+ Compare: https://peptrackerpro.com/compare?select=retatrutide Track in App: https://app.peptrackerpro.com/?add=retatrutide ### Semaglutide High Evidence A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. Weight Management (https://peptrackerpro.com/benefits/weight-management)Appetite Regulation (https://peptrackerpro.com/benefits/appetite-regulation)Metabolism (https://peptrackerpro.com/benefits/metabolism)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)+3 more View Details: https://peptrackerpro.com/peptides/semaglutide \+ Compare: https://peptrackerpro.com/compare?select=semaglutide Track in App: https://app.peptrackerpro.com/?add=semaglutide ### Survodutide Medium Evidence A dual GLP-1/glucagon receptor agonist with FDA Breakthrough Therapy designation for MASH and Priority Review NDA filed February 2026. Phase 3 SYNCHRONIZE-1 reported 16.6% weight loss at 76 weeks; approval possible Q3 2026. View Details: https://peptrackerpro.com/peptides/survodutide \+ Compare: https://peptrackerpro.com/compare?select=survodutide Track in App: https://app.peptrackerpro.com/?add=survodutide ### Tirzepatide High Evidence A dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes, weight management, and MASH with liver fibrosis. Weight Management (https://peptrackerpro.com/benefits/weight-management)Appetite Regulation (https://peptrackerpro.com/benefits/appetite-regulation)Metabolism (https://peptrackerpro.com/benefits/metabolism)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)+1 more View Details: https://peptrackerpro.com/peptides/tirzepatide \+ Compare: https://peptrackerpro.com/compare?select=tirzepatide Track in App: https://app.peptrackerpro.com/?add=tirzepatide ### HRS9531 (KAI-9531) Medium Evidence An investigational once-weekly injectable dual GLP-1/GIP receptor agonist - the same peptide class as tirzepatide (Zepbound/Mounjaro) - developed by China's Jiangsu Hengrui Pharmaceuticals as HRS9531 and licensed to U.S.-based Kailera Therapeutics, which is developing it globally (outside Greater China) as KAI-9531. In the pivotal 48-week Phase 3 GEMINI-1 trial in China (NCT06396429; 567 adults with obesity or overweight without diabetes), once-weekly HRS9531 produced mean weight loss of about 17.4-19.2% at the 4 mg and 6 mg doses (per-protocol/hypothetical estimand) versus roughly 1.4% for placebo, with about 44% of 6 mg patients losing at least 20% of body weight and broad improvements in blood pressure, lipids, insulin resistance, and inflammation (hsCRP). An earlier Phase 2 trial reported about 23.6% mean weight loss at the higher 8 mg dose by week 36 with no plateau. Hengrui has submitted a marketing application to China's NMPA for chronic weight management, and Kailera began a global Phase 3 program (KAI-9531) evaluating higher maintenance doses (8 mg and 10 mg) and longer treatment by late 2025. HRS9531/KAI-9531 is investigational, is not approved outside of any regulatory review in China, and is not a supplement or research chemical; it is studied only in clinical trials. Weight Management (https://peptrackerpro.com/benefits/weight-management)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)Body Composition (https://peptrackerpro.com/benefits/body-composition)Metabolism (https://peptrackerpro.com/benefits/metabolism)+1 more View Details: https://peptrackerpro.com/peptides/hrs9531 \+ Compare: https://peptrackerpro.com/compare?select=hrs9531 Track in App: https://app.peptrackerpro.com/?add=hrs9531 ## Structured data ```json [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Maridebart Cafraglutide (MariTide)", "description": "Amgen's once-monthly injectable GIP receptor antagonist and GLP-1 receptor agonist, showing up to 20% weight loss in phase 2 trials with a unique mechanism that blocks GIP while activating GLP-1.", "url": "https://peptrackerpro.com/peptides/maridebart-cafraglutide", "lastReviewed": "2026-06-20", "reviewedBy": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "isPartOf": { "@type": "WebSite", "name": "PepTracker Pro", "url": "https://peptrackerpro.com" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Peptides", "item": "https://peptrackerpro.com/peptides" }, { "@type": "ListItem", "position": 3, "name": "Maridebart Cafraglutide (MariTide)", "item": "https://peptrackerpro.com/peptides/maridebart-cafraglutide" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "People researching once-monthly weight loss injection options?", "acceptedAnswer": { "@type": "Answer", "text": "Maridebart Cafraglutide (MariTide) is a research peptide studied in preclinical models. Amgen's once-monthly injectable GIP receptor antagonist and GLP-1 receptor agonist, showing up to 20% weight loss in phase 2 trials with a unique mechanism that blocks GIP while activating GLP-1." } }, { "@type": "Question", "name": "Those interested in how GIP antagonism differs from GIP agonism?", "acceptedAnswer": { "@type": "Answer", "text": "Maridebart Cafraglutide (MariTide) is a research peptide studied in preclinical models. Amgen's once-monthly injectable GIP receptor antagonist and GLP-1 receptor agonist, showing up to 20% weight loss in phase 2 trials with a unique mechanism that blocks GIP while activating GLP-1." } }, { "@type": "Question", "name": "Individuals following the obesity drug pipeline beyond semaglutide and tirzepatide?", "acceptedAnswer": { "@type": "Answer", "text": "Maridebart Cafraglutide (MariTide) is a research peptide studied in preclinical models. Amgen's once-monthly injectable GIP receptor antagonist and GLP-1 receptor agonist, showing up to 20% weight loss in phase 2 trials with a unique mechanism that blocks GIP while activating GLP-1." } }, { "@type": "Question", "name": "Researchers studying incretin biology and receptor pharmacology?", "acceptedAnswer": { "@type": "Answer", "text": "Maridebart Cafraglutide (MariTide) is a research peptide studied in preclinical models. Amgen's once-monthly injectable GIP receptor antagonist and GLP-1 receptor agonist, showing up to 20% weight loss in phase 2 trials with a unique mechanism that blocks GIP while activating GLP-1." } } ] } ] ```